Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

Completed · Phase 2

Conditions studied: Hepatitis C

In brief

The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.

Key facts

Study ID

NCT02175966

Run by

Bristol-Myers Squibb

People needed

35

Starts

2014-07-28

Expected to finish

2015-12-17

Last updated by the study team

2020-08-11

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and Females ≥18 years of age, inclusive
• Chronic HCV infection Genotype 1 only
• Non-cirrhotic
• Treatment naive subjects with no previous exposure to an Interferon formulation (ie, IFNα, pegIFNα), ribavirin (RBV) or HCV Direct Acting Antiviral (DAA) (protease, polymerase inhibitor, etc.)

You may not qualify if…

• HCV Genotype other than Genotype 1
• Documented or suspected hepatocellular carcinoma
• Evidence of decompensated liver disease
• Contraindication(s) to Peg/RBV therapy

Where it is running

• Inland Empire Liver Foundation — Rialto, California, United States
• Northwestern Memorial Hospital — Chicago, Illinois, United States
• Northwestern University Feinberg School Of Medicine — Chicago, Illinois, United States
• Indiana University Health - University Hospital — Indianapolis, Indiana, United States
• Indiana University Med Center — Indianapolis, Indiana, United States
• Johns Hopkins University — Lutherville, Maryland, United States
• Texas Liver Institute — San Antonio, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.